AR048332A1 - Formulaciones de tableta recubierta y metodo - Google Patents
Formulaciones de tableta recubierta y metodoInfo
- Publication number
- AR048332A1 AR048332A1 ARP050101158A ARP050101158A AR048332A1 AR 048332 A1 AR048332 A1 AR 048332A1 AR P050101158 A ARP050101158 A AR P050101158A AR P050101158 A ARP050101158 A AR P050101158A AR 048332 A1 AR048332 A1 AR 048332A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- tablet
- coating
- medicament
- coated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulacion de tableta recubierta que incluye un medicamento tal como el agonistanista doble de PPAR alfa/gamma, peliglitazar o muraglitazar, Las tabletas recubiertas incluyen un nucleo de la tableta, tal recubrimiento puede incluir una o más capas, al menos una capa del cual está formada de medicamento y uno o más polímeros de recubrimiento, preferentemente un polímero a base de hidroxipropilmetil celulosa. Método para formar la tableta recubierta por medio de una técnica de recubrimiento con secado por rociado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55633104P | 2004-03-25 | 2004-03-25 | |
US64887205P | 2005-02-01 | 2005-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048332A1 true AR048332A1 (es) | 2006-04-19 |
Family
ID=35064439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101158A AR048332A1 (es) | 2004-03-25 | 2005-03-23 | Formulaciones de tableta recubierta y metodo |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050214373A1 (es) |
EP (1) | EP1734921A2 (es) |
JP (1) | JP2007530565A (es) |
KR (1) | KR20060128028A (es) |
AR (1) | AR048332A1 (es) |
AU (1) | AU2005228988A1 (es) |
BR (1) | BRPI0509194A (es) |
CA (1) | CA2560812A1 (es) |
MX (1) | MXPA06010775A (es) |
PE (1) | PE20060160A1 (es) |
RU (1) | RU2006137672A (es) |
TW (1) | TW200534879A (es) |
WO (1) | WO2005094786A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
RU2401125C2 (ru) | 2004-12-27 | 2010-10-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ стабилизации лекарственного средства против деменции |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CN101453996B (zh) * | 2006-04-03 | 2016-05-11 | 伊萨·奥迪迪 | 药物递送组合物 |
CA2648280C (en) | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
AU2008268537B2 (en) * | 2007-06-22 | 2012-11-01 | Bristol-Myers Squibb Holdings Ireland | Tableted compositions containing atazanavir |
ES2360336T3 (es) * | 2007-06-22 | 2011-06-03 | Bristol-Myers Squibb Company | Composiciones en comprimidos que contienen atazanavir. |
DE602008005462D1 (de) * | 2007-06-22 | 2011-04-21 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
MX2009013504A (es) * | 2007-06-22 | 2010-03-26 | Bristol Myers Squibb Co | Composiciones comprimidas que tienen atazanavir. |
KR101944124B1 (ko) | 2010-11-24 | 2019-01-30 | 멜린타 서브시디어리 코프. | 약학 조성물 |
EA201492026A1 (ru) | 2012-05-07 | 2015-09-30 | Байер Фарма Акциенгезельшафт | Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
US5428048A (en) * | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
JP2002540102A (ja) * | 1999-03-22 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | cGMPホスホジエステラーゼの縮合ピリドピリダジン阻害剤 |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
CA2390557A1 (en) * | 1999-11-11 | 2001-05-17 | Kyorin Pharmaceutical Co., Ltd. | Solid preparations for oral use |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
CA2444569C (en) * | 2001-04-18 | 2011-01-04 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
-
2005
- 2005-03-18 TW TW094108464A patent/TW200534879A/zh unknown
- 2005-03-21 US US11/085,710 patent/US20050214373A1/en not_active Abandoned
- 2005-03-22 EP EP05726069A patent/EP1734921A2/en not_active Withdrawn
- 2005-03-22 CA CA002560812A patent/CA2560812A1/en not_active Abandoned
- 2005-03-22 JP JP2007505121A patent/JP2007530565A/ja active Pending
- 2005-03-22 WO PCT/US2005/009615 patent/WO2005094786A2/en not_active Application Discontinuation
- 2005-03-22 AU AU2005228988A patent/AU2005228988A1/en not_active Abandoned
- 2005-03-22 MX MXPA06010775A patent/MXPA06010775A/es not_active Application Discontinuation
- 2005-03-22 RU RU2006137672/15A patent/RU2006137672A/ru unknown
- 2005-03-22 BR BRPI0509194-2A patent/BRPI0509194A/pt not_active Application Discontinuation
- 2005-03-22 KR KR1020067019557A patent/KR20060128028A/ko not_active Application Discontinuation
- 2005-03-23 AR ARP050101158A patent/AR048332A1/es not_active Application Discontinuation
- 2005-03-28 PE PE2005000343A patent/PE20060160A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1734921A2 (en) | 2006-12-27 |
WO2005094786A3 (en) | 2006-05-04 |
AU2005228988A1 (en) | 2005-10-13 |
CA2560812A1 (en) | 2005-10-13 |
RU2006137672A (ru) | 2008-04-27 |
PE20060160A1 (es) | 2006-03-15 |
US20050214373A1 (en) | 2005-09-29 |
BRPI0509194A (pt) | 2007-08-28 |
TW200534879A (en) | 2005-11-01 |
JP2007530565A (ja) | 2007-11-01 |
KR20060128028A (ko) | 2006-12-13 |
WO2005094786A2 (en) | 2005-10-13 |
MXPA06010775A (es) | 2006-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048332A1 (es) | Formulaciones de tableta recubierta y metodo | |
AR049062A1 (es) | Formulacion de tableta revestida que contiene un inhibidor dpp4, como saxagliptina, y metodo | |
CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
BR112012024139A2 (pt) | formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide. | |
ECSP109934A (es) | Compuesto - 946 | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
AR090269A1 (es) | Composicion farmaceutica y sus usos | |
CL2012001404A1 (es) | Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion. | |
CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
DOP2006000050A (es) | Una formulación sólida de dosificación farmaceútica | |
AR087239A2 (es) | Formulaciones farmaceuticas solidas que comprenden telmisartan | |
GT200600500A (es) | Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina | |
ECSP19035322A (es) | Formulaciones farmacéuticas | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
ECSP099629A (es) | Composición farmacéutica | |
CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
AR034335A1 (es) | Composiciones de revestimiento por inmersion que contienen eteres celulosa | |
AR104257A1 (es) | Tableta de ribociclib | |
CL2009000964A1 (es) | Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior. | |
CL2014001534A1 (es) | Combinacion de dosis fija que comprende clorhidrato de benazeprilo y pimobendan en forma de un comprimido de dos capas; procedimiento de fabricacion y uso en el tratamiento de la insuficiencia cardiaca congestiva en perros. | |
AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
ES2623281T3 (es) | Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |